Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT03294889 Not yet recruiting - Prostate Cancer Clinical Trials

ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer

Start date: October 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The main objective of the phase I/II trial is to determine the safety and efficacy of a single fraction SBRT at a dose of 19 Gy in patients with localized prostate cancer.

NCT ID: NCT03294122 Recruiting - Prostate Cancer Clinical Trials

Predictors of Normal Tissue Response From the Microenvironment in Radiotherapy for Prostate and Head-and-neck Cancer

MICROLEARNER
Start date: February 2, 2017
Phase: N/A
Study type: Observational

The main idea behind MICRO-LEARNER is to provide new insights about the response of healthy tissues to radiation by using information from the micro-environment obtained by biological measurements and imaging. This new knowledge will be included in current available predictive models of radio-induced toxicity, thus allowing to add unique biological characteristics of patients to dosimetry and treatment/clinical related variables. MICRO-LEARNER focuses on prostate cancer (PCa) and head-and-neck cancer (HNCa). For both cancers, radiotherapy is effectively used as curative treatment, in single modality or within a multidisciplinary approach including surgery (PCa) and/or chemotherapy (HNCa). Prediction and reduction of radio-induced side effects are becoming a priority: for PCa, high survival rates should be accompanied by a very low rate of moderate/severe toxicities; for HNCa, there is the need to tailor radiation dose according to disease recurrence risk profile. The shared aim of both cancers is to balance the improvement in outcome with a well-tolerated toxicity profile. Recent research indicates that the intestinal/salivary bacteria are strongly suspected of being very important in mediating the response to inflammation and lesions. Although their balance deeply changes during radiotherapy, studies done so far in the field of the microbiota-host relationship in radiotherapy have not addressed their role in insurgence of radiation toxicity. In this study, the investigators will assess how microbial populations evolve and how this influences the host and radiation induced toxicity in a significant number of patients. Moreover, the individual response at the tissue microstructure level, through analysis of images with advanced bioengineering techniques, will be determined. Results from this research, besides suggesting new ways to predict patients at risk of relevant side-effects, may also suggest possible treatments to change the baseline microbiota of patients at high risk or to modify it during therapy, in order to mitigate toxicity. Understanding the microbiota-radiotherapy interaction may thus lead to novel, effective and inexpensive ways of assessing and managing complications of cancer treatment.

NCT ID: NCT03293602 Not yet recruiting - Prostate Cancer Clinical Trials

MISOBOLD - Prostate Cancer Hypoxia Using BOLD MRI and 18F-MISO PET Imaging

MISOBOLD
Start date: November 1, 2017
Phase: N/A
Study type: Interventional

This feasibility exploratory study objective is to assess the ability of combined MRI BOLD and 18F-MISO PET imaging to visualize tumor hypoxia compare to histological results obtained after radical prostatectomy in order to, in time, be able to identify patient with bad prognostic and to offer them the best therapeutic strategy.

NCT ID: NCT03292874 Active, not recruiting - Prostate Cancer Clinical Trials

High Resolution MRI Study for Prostate Cancer

Start date: September 13, 2017
Phase: N/A
Study type: Interventional

This high resolution MRI (hrMRI), along with stand MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance. Changes in lesion size and ADC values will be assessed on the serial studies. This study evaluates the hypothesis that hrMRI will detect changes that sMRI cannot detect and that these changes will correlate with prostate cancer progression as determined on prostate biopsy.

NCT ID: NCT03290508 Recruiting - Prostate Cancer Clinical Trials

Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

Start date: September 14, 2017
Phase: N/A
Study type: Observational [Patient Registry]

This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients with Prolaris low-risk scores without negatively impacting patient oncologic outcomes, thereby sparing low-risk patients from unnecessary treatments and associated side-effects.

NCT ID: NCT03290417 Recruiting - Prostate Cancer Clinical Trials

Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer

Start date: September 7, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to see if eating vitamin D, omega 3 and turmeric (curcumin) slows the growth of prostate cancer in men on active surveillance.

NCT ID: NCT03284684 Not yet recruiting - Breast Cancer Clinical Trials

Kinetics of Perioperative Circulating DNA in Cancer Surgery

Periop ctDNA
Start date: September 2017
Phase: N/A
Study type: Observational

The aim of this study was to determine the kinetics of perioperative circulating DNA in three types of cancer. This first step will enable further studies comparing the potential impact of certain techniques or anesthetic products on cancer surgery.

NCT ID: NCT03284151 Recruiting - Prostate Cancer Clinical Trials

Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma

Start date: January 2015
Phase: N/A
Study type: Observational [Patient Registry]

Focused stereotactic radiation treatment of localized prostatic adenocarcinoma. in order to quantify the delay between the focused treatment and the salvage procedure.

NCT ID: NCT03279250 Recruiting - Prostate Cancer Clinical Trials

Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence

Start date: October 13, 2017
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if adding abiraterone acetate and standard of care prednisone to the combination of apalutamide and a standard type of drug called an LHRH agonist can help to control prostate cancer when given before surgery. The safety of these drug combinations will also be studied. This is an investigational study. Apalutamide is not FDA approved or commercially available. It is currently being used for research purposes only. The combination of abiraterone acetate, LHRH agonists, and prednisone is FDA approved and commercially available for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drug combinations being used in this study are considered investigational. Up to 66 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT03278197 Recruiting - Prostate Cancer Clinical Trials

Evaluation of a Web-based Decision Aid Tool for Prostate Cancer Patients

ProDecA
Start date: January 2015
Phase: N/A
Study type: Interventional

Patients diagnosed with localized prostate cancer may be eligible for different treatment options. MAASTRO Clinic (MAAStricht Radiation Oncology) developed a web-based decision aid tool for these patients. The goal of the tool is to help patients to understand the treatments, and empower the patients to participate in the decision making process. The aim of this study is threefold: (A) user-testing and validation of the tool, by using a systematically development process compliant with the IPDAS (International Patients Decision Aids Standards) criteria (B) establish the impact of the tool on the decision making process; (C) identify barriers and facilitators for the implementation of shared decision making and the tool in clinical practice. The study covers 3 phases: 1. Development phase 1.1 Assess decisional needs of patients and clinicians. 1.2 Test patients' and clinicians' comprehensibility, acceptability and usability on the alpha-version of the tool. 1.3 Value clarification: Delphi study with former prostate cancer patients to determine the most important patient preferences and value clarification aspects the decision aid should include. 2. Implementation phase: Develop an implementation and dissemination plan for shared decision-making which is based on the evaluation of barriers and facilitators for the use of patient decision aid tools in clinical practice. 3. Evaluation phase: Establish the impact of on knowledge, decisional conflict and the shared decision-making process, as well as the extent to which clinicians involve patients in decision-making. A mixed method will be used. It comprises structured interviews combined with think aloud and questionnaires with stakeholders involved in the whole process of development, implementation and evaluation (patients, urologists, radiotherapists, nurses, general practitioners, patient organizations, and insurance companies).